Silence Therapeutics plc
corporate_fare Company Profile
Silence Therapeutics plc (NASDAQ:SLN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for SLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-19, rated 10/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for SLN spans 8-K, SCHEDULE 13D/A, 4, 424B5.
Recent high-impact activity:
- Merck KGaA to Acquire Silence Therapeutics for $20.00/ADS in $1.3B All-Cash Deal
- Merck KGaA to Acquire Silence Therapeutics in Takeover Deal
- Silence Therapeutics Closes $201M Upsized Offering After Full Underwriter Option Exercise
- Controlling Shareholder Richard Griffiths Sells $87.7M in ADSs, Stake Falls to 7.97%
- 10% Owner Richard Griffiths Sells 5.48M ADSs for ~$88M
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2,418,248 shares in SLN as of the October 30, 2026 settlement, a 17.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 45.2% of SLN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for SLN, detected from its recent SEC filings · based on capital-structure filings through 2026-08-12.
Offering Priced at $13.50/ADS · Net Proceeds of $164 Million
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →